Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique during both initial implantation and subsequent refill procedures, with ...

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...

AI-based screening for pediatric DRD is more cost-effective and increases screening rates compared to traditional ECP methods ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...